103818-46-8 Usage
General Description
N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine, commonly known as MBDB, is a chemical compound that belongs to the amphetamine and phenethylamine classes. It is a psychoactive substance that is structurally similar to the popular recreational drug MDMA, or ecstasy. MBDB is known to produce empathogenic effects, causing feelings of empathy, emotional openness, and increased sociability in users. It is also reported to induce mild stimulant and psychedelic effects. MBDB is a serotonin-norepinephrine-dopamine releasing agent, meaning it increases the levels of these neurotransmitters in the brain, leading to its psychoactive effects. The compound is not approved for medical use and is classified as a controlled substance in many countries due to its potential for abuse and dependence.
Check Digit Verification of cas no
The CAS Registry Mumber 103818-46-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,8,1 and 8 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 103818-46:
(8*1)+(7*0)+(6*3)+(5*8)+(4*1)+(3*8)+(2*4)+(1*6)=108
108 % 10 = 8
So 103818-46-8 is a valid CAS Registry Number.
InChI:InChI=1/C12H17NO2/c1-3-11(13-2)6-9-4-5-10-8-14-15-12(10)7-9/h4-5,7,11,13H,3,6,8H2,1-2H3
103818-46-8Relevant articles and documents
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: Representatives of a novel therapeutic class
Nichols,Hoffman,Oberlender,Jacob III,Shulgin
, p. 2009 - 2015 (1986)
The α-ethyl phenethylamine derivative 1-(1,3-benzodioxol-5-yl)-2-butanamine was prepared. An asymmetric synthesis was used to prepare the enantiomers of this compound and the related α-methyl homologue (MDA). The racemates and enantiomers of both compounds were evaluated in the two-lever drug discrimination assay in rats trained to discriminate saline from 0.08 mg/kg of LSD tartrate. Stimulus generalization occurred with the racemate and the R-(-)enantiomer of the α-methyl homologue and the S-(+)enantiomer of the α-ethyl primary amine. No generalization occurred with the other enantiomers or with the N-methyl derivatives of either series. Human psychopharmacology studies revealed that the N-methyl derivative of the title compound was nonhallucinogenic and that it had a new, novel psychoactive effect. It is suggested that this compound is the prototype of a new pharmacologic class that may have value in facilitating psychotherapy and that this class be designated as entactogens.
